Ascorbic acid improves thrombotic function of platelet during orthotopic living donor liver transplantation

Ascorbic acid improves thrombotic function of platelet during orthotopic living donor liver transplantation via modulation of the function of E3 ubiquitin ligase Cbl-b and c-Cbl

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0002503

Enrollment

Registered

2017-10-20

Start date

2014-07-21

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : 1) Thromboelastography (ROTEM®) In order to investigate whether ascorbic acid has an effect on the platelet function during liver transplantation, we first performed thromboelast

- a control group (C group

0.36 mL of blood sample), - a normal saline group (N group

0.33 mL of blood sample + 0.03 mL of 0.9&#37

normal saline) - an ascorbic acid group (A group

0.33 mL of blood sample + 0.03 mL of 200 ?mol of L-ascorbic acid dissolved in 0.9&#37

normal saline). 2) Washed platelet preparation At the same time as performing thromboelastography, 12 mL of fresh blood was collected from arterial catheter placed in the right radial artery and div

4 mL of fresh blood N group

3.6 mL of fresh blood + 0.4 mL of 0.9&#37

normal saline A group

3.6 mL of fresh blood + 0.4 mL of 200 ?mol of L-ascorbic acid dissolved in 0.9&#37

normal saline

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Recipients who underwent elective living donor liver transplantation at our hospital, a university-affiliated hospital, were enrolled into this study.

Exclusion criteria

Exclusion criteria: In order to minimize factors that can affect platelet function during liver transplantation, we excluded patients who had previously received liver transplantation because of the possibility of large amount of bleeding and transfusion, and patients who have been transfused any kind of blood component within 1 week before surgery. We also excluded patients who received platelet concentrates before blood sample was taken at the time of 120 minutes after reperfusion.

Design outcomes

Primary

Measure	Time frame
Thromboelastography (ROTEM®) : CT (coagulation time), CFT (clot formation time), alpha-angle, MCF (maximum clot firmness), LI60 (lysis index 60 min after CT), ML (maximum lysis) and AUC (area under the curve)	—

Secondary

Measure	Time frame
Washed platelet preparation and Immunoblottings	—

Countries

Korea, Republic of

Contacts

Public ContactJi hye Kwon

Samsung Medical Center

kwonjh0828@hanmail.net+82-2-3410-0369

Outcome results